Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3609081 | 1.00 | KDM4E (0.39) | KDM4EKMT2AMEN1ADRA2BMAPK1 | |
| SCHEMBL3611465 | 0.88 | KDM4E (0.42) | KDM4EKMT2AMEN1ADRA2BMAPK1 | |
| SCHEMBL13502976 | 0.81 | MEN1 (0.39) | KDM4EKMT2AMEN1MAPK1ALDH1A1 | |
| SCHEMBL6217328 | 0.77 | ACACB (0.31) | ALDH1A1 | |
| SCHEMBL9565709 | 0.74 | KDM4E (0.44) | KDM4EKMT2AMEN1ADRA2BMAPK1 | |
| SCHEMBL25379757 | 0.69 | CES2 (0.31) | — | |
| SCHEMBL9746643 | 0.69 | CES2 (0.31) | — | |
| SCHEMBL9748463 | 0.69 | CES2 (0.31) | — | |
| SCHEMBL10862560 | 0.69 | NPSR1 (0.45) | KDM4EKMT2AMEN1MAPK1ALDH1A1 | |
| SCHEMBL8136234 | 0.69 | KDM4E (0.52) | KDM4EKMT2AMEN1ADRA2BMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029938-A1 | PROCESS FOR THE PREPARATION OF AN ANTIBACTERIAL QUINOLONE COMPOUND | FARMAPROJECTS, S. A. (ES) | 2010-02-04 | — | — | US | disclosed |
| WO-2008077643-A1 | PROCESS FOR THE PREPARATION OF AN ANTIBACTERIAL QUINOLONE COMPOUND | FARMAPROJECTS, S.A. (ES) | 2008-07-03 | — | — | WO | disclosed |
| EP-1939206-A1 | Process for the preparation of an antibacterial quinolone compound | Farmaprojects, S.A. (ES) | 2008-07-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029938-A1 | PROCESS FOR THE PREPARATION OF AN ANTIBACTERIAL QUINOLONE COMPOUND | CYP3A4, CYP4B1, CYP4F11 | KDM4E 998/4885KMT2A 3906/4885MEN1 3155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.